Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems

Neuroscientist

Volumn 9, Issue 1, 2003, Pages 23-36

  Zhou, Fu Ming ^a   Wilson, Charles ^b   Dani, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Acetylcholine; Basal ganglia; Dopamine; Mesolimbic; Nigrostriatal; Nucleus accumbens; Parkinson's disease; Striatum; Substantia nigra; Ventral tegmental area

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CHOLINERGIC RECEPTOR; DOPAMINE; DOPAMINE RECEPTOR; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR;

ACETYLCHOLINE RELEASE; ACTION POTENTIAL; ADDICTION; BASAL GANGLION; BEHAVIOR; CHOLINERGIC SYSTEM; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FUNCTIONAL ANATOMY; GILLES DE LA TOURETTE SYNDROME; HUNTINGTON CHOREA; INTERNEURON; LEARNING; MEMORY; MESENCEPHALON; MESOLIMBIC DOPAMINERGIC SYSTEM; MOTOR CONTROL; MOTOR COORDINATION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NUCLEUS ACCUMBENS; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; PEDUNCULAR ANSA; PONS ANGLE; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; REWARD; SENSORIMOTOR FUNCTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ACETYLCHOLINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTERNEURONS; NEURONS; PARKINSON DISEASE; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; SUBSTANTIA NIGRA; TEGMENTUM MESENCEPHALI;

EID: 0037309371     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858402239588     Document Type: Review

References (146)

1. 1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. J Neurosci 17:8498-505.
2. 2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci 3:226-30.
3. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, and others. 1997. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117-36.
4. Alcantara AA, Mrzljak L, Jakab RL, Levey AI, Hersch SM, Goldman-Rakic PS. 2001. Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefrontostriatal pathways. J Comp Neurol 434:445-60.
5. Aosaki T, Kiuchi K, Kawaguchi Y. 1998. Dopamine D1-like receptor activation excites rat striatal large aspiny neurons in vitro. J Neurosci 18:5180-90.
6. Barbour B, Hausser M. 1997. Intersynaptic diffusion of neurotransmitter. Trends Neurosci 20:377-84.
7. Behmand RA, Harik SI. 1992. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J Neurochem 58:776-9.
8. Belluardo N, Mudo G, Blum M, Fuxe K. 2000. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 113:21-34.
9. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, and others. 2000. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 55:1350-8.
10. Bennett BD, Wilson CJ. 1999. Spontaneous activity of neostriatal cholinergic interneurons in vitro. J Neurosci 19:5586-96.
11. 5 dopamine receptors in primate brain. J Neurosci 15:7821-36.
12. Bernard V, Laribi O, Levey AI, Bloch B. 1998. Subcellular redistribution of m2 muscarinic acetylcholine receptors in striatal interneurons in vivo after acute cholinergic stimulation. J Neurosci 18:10207-18.
13. Bernard V. Normand E, Bloch B. 1992. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 12:3591-600.
14. Billard W, Binch H 3rd, Crosby G, McQuade RD. 1995. Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J Pharmacol Exp Ther 273:273-9.
15. Björklund A, Lindvall O. 1984. Dopamine-containing systems in the CNS. In: Björklund A, Hökfelt T, editors. Classical transmitters in the CNS, Part I. Amsterdam: Elsevier. p 55-122.
16. Bolam JP, Hanley JJ, Booth PA, Bevan MD. 2000. Synaptic organisation of the basal ganglia. J Anat 196:527-42.
17. Bolam JP, Wainer BH, Smith AD. 1984. Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience 12:711-8.
18. Bonanno G, Marchi M, Raiteri M. 1985. Activation of muscarinic receptors on striatal synaptosomes increases the release of endogenous dopamine. Neuropharmacology 24:261-4.
19. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, and others. 1997. Acute effects of cocaine on human brain activity and emotion. Neuron 19:591-11.
20. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. 2001. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21:1033-8.
21. Butcher LL, Woolf NJ. 1984. Histochemical distribution of acetylcholinesterase in the central nervous system: clues to the localization of cholinergic neurons. In: Björklund A, Hökfelt T, Kuhar MJ, editors. Classical transmitters and transmitter receptors in the CNS, Part II. Amsterdam: Elsevier. p 1-50.
22. Calabresi P, Centonze D, Gubellini P. Pisani A, Bernardi G. 2000. Acetylcholine-mediated modulation of striatal function. Trends Neurosci 23:120-6.
23. Calabresi P, Centonze D, Pisani A, Sancesario G, North RA, Bernardi G. 1998. Muscarinic IPSPs in rat striatal cholinergic interneurones. J Physiol 510:421-7.
24. Carlsson A. 2002. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109:777-87.
25. Carr LA, Rowell PP. 1990. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology 29:311-4.
26. Caulfield MP, Birdsall NJ. 1998. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-90.
27. Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, and others. 2002. Distribution and pharmacology of α6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 22:1208-17.
28. Charpantier E, Barnéoud P, Moser P, Besnard F, Sgard F. 1998. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 9:3097-101.
29. Chevalier G, Deniau JM. 1990. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 13:277-80.
30. Cicchetti F, Prensa L, Wu Y, Parent A. 2000. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev 34:80-101.
31. Clemens P, Baron JA, Coffey D, Reeves A. 1995. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology 117:253-6.
32. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP. 2000. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci 21:211-7.
33. Damsma G, Tham CS, Robertson GS, Fibiger HC. 1990. Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat. Eur J Pharmacol 186:335-8.
34. Dani JA. 2001. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49:166-74.
35. Dani JA, De Biasi M. 2001. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439-46.
36. Dani JA, Ji D, Zhou FM. 2001. Synaptic plasticity and nicotine addiction. Neuron 31:349-52.
37. Dani JA, Radcliffe KA, Pidoplichko VI. 2000. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 393:31-8.
38. De Boer P, Abercrombie ED. 1996. Physiological release of striatal acetylcholine in vivo: modulation by D, and D, dopamine receptor subtypes. J Pharmacol Exp Ther 277:775-83.
39. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-5.
40. de Rover M, Schoffelmeer ANM, Kits KS. 2000. Cholinergic modulation of GABAergic and glutamatergic synaptic transmission in the nucleus accumbens (NAC) shell of the rat. The 10th Neuropharmacology Conference Abstract Book. p 169.
41. Descarries L, Mechawar N. 2000. Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. Prog Brain Res 125:27-47.
42. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P. MacGregor RR, and others. 1993. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci U S A 90:11816-20.
43. Diana M, Tepper JM. 2002. Electrophysiological pharmacology of mesencephalic dopaminergic neurons. In: Di Chiara G, editor. Handbook of experimental pharmacology, Vol. 154. Dopamine in the CNS II. Berlin, Germany: Springer-Verlag. p 1-63.
44. Di Chiara G, Morelli M, Consolo S. 1994. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:228-33.
45. Dolezal V, Tucek S. 1998. The effects of brucine and alcuronium on the inhibition of [3H]acetylcholine release from rat striatum by muscarinic receptor agonists. Br J Pharmacol 124:1213-8.
46. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. 1999. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 14:1011-3.
47. Eglen RM, Choppin A, Watson N. 2001. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 22:409-14.
48. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. 1994. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 116:117-9.
49. Fahn S, Burke R, Stern Y. 1990. Antimuscarinic drugs in the treatment of movement disorders. Prog Brain Res 84:389-97.
50. Falkenburger BH, Barstow KL, Mintz IM. 2001. Dendrodendritic inhibition through reversal of dopamine transport. Science 293:2465-70.
51. Fiorillo CD, Williams JT. 2000. Cholinergic inhibition of ventral midbrain dopamine neurons. J Neurosci 20:7855-60.
52. Forster GL, Yeomans JS, Takeuchi J, Blaha CD. 2002. M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J Neurosci 22:RC190.
53. Fratiglioni L, Wang HX. 2000. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 113:117-20.
54. Freund TF, Powell JF, Smith AD. 1984. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13:1189-215.
55. Galarraga E, Hernandez-Lopez S, Reyes A, Miranda I, Bermudez-Rattoni F, Vilchis C, and others. 1999. Cholinergic modulation of neostriatal output: a functional antagonism between different types of muscarinic receptors. J Neurosci 19:3629-38.
56. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. 2001. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 98:15312-7.
57. Gerfen CR. 2000. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23:S64-70.
58. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J, and others. 1999. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 96:1692-7.
59. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, and others. 1999. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 96:10483-8.
60. Gonon F. 1997. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J Neurosci 17:5972-8.
61. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. 1999. Smoking and Parkinson's disease: a dose-response relationship. Neurology 52:115-9.
62. Grace AA. 2000. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31:330-41.
63. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. 1996. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713-16.
64. Graybiel AM, Canales JJ. 2001. The neurobiology of repetitive behaviors: clues to the neurobiology of Tourette syndrome. Adv Neurol 85:123-31.
65. Grillner P, Berretta N, Bernardi G, Svensson TH, Mercuri NB. 2000. Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. Neuroscience 96:299-307.
66. Grillner P, Bonci A, Svensson TH, Bernardi G, Mercuri NB. 1999. Presynaptic muscarinic M3 receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon. Neuroscience 91:557-65.
67. Gronier B, Perry KW, Rasmussen K. 2001. Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology (Berl) 147:347-55.
68. Gronier B, Rasmussen K. 1998. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br J Pharmacol 124:455-64.
69. Haber SN, Fudge JL, McFarland NR. 2000. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 20:2369-82.
70. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. 2001. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 50:780-6.
71. 2+ currents and excitability via a novel PLCβ1-IP3-calcineurin-signaling cascade. J Neurosci 20:8987-95.
72. Hornykiewicz O. 1998. Biochemical aspects of Parkinson's disease. Neurology 51:S2-9.
73. 2+ currents in rat striatal neurons through parallel pathways. J Neurosci 15:458-69.
74. Hsu KS, Yang CH, Huang CC, Gean PW. 1996. Carbachol induces inward current in neostriatal neurons through M1-like muscarinic receptors. Neuroscience 73:751-60.
75. Imperato A, Obinu MC, Casu MA, Mascia MS, Dazzi L, Gessa GL. 1993. Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors. J Pharmacol Exp Ther 266:557-62.
76. Inase M, Li B-M, Tanji J. 1997. Dopaminergic modulation of neuronal activity in the monkey putamen through D1 and D2 receptors during a delayed Go/Nogo task. Exp Brain Res 117:207-18.
77. Ince E, Ciliax BJ, Levey AI. 1997. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27:357-66.
78. Ishikawa A, Miyatake T. 1993. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 117:28-32.
79. Jones IW, Bolam JP, Wonnacott S. 2001. Presynaptic localization of the nicotinic acetylcholine receptor β2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurons. J Comp Neurol 439:235-47.
80. Jones S, Sudweeks S, Yakel JL. 1999. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22:555-61.
81. Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ, and others. 2000. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 289:633-7.
82. Kapur S, Seeman P. 2001. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-9.
83. Kawaguchi Y, Wilson CJ, Emson PC. 1990. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 10:3421-38.
84. Kawashima K, Hayakawa T, Kashima Y, Suzuki T, Fujimoto K, Oohata H. 1991. Determination of acetylcholine release in the striatum of anesthetized rats using in vivo microdialysis and a radioimmunoassay. J Neurochem 57:882-7.
85. Kayadjanian N, Schofield WN, Andren J, Sirinathsinghji DJ, Besson MJ. 1999. Cortical and nigral deafferentation and striatal cholinergic markers in the rat dorsal striatum: different effects on the expression of mRNAs encoding choline acetyltransferase and muscarinic ml and m4 receptors. Eur J Neurosci 11:3659-68.
86. Kincaid AE, Zheng T, Wilson CJ. 1998. Connectivity and convergence of single corticostriatal axons. J Neurosci 18:4722-31.
87. Koos T, Tepper JM. 1999. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2:467-72.
88. Koos T, Tepper JM. 2002. Dual cholinergic control of fast-spiking interneurons in the neostriatum. J Neurosci 22:529-35.
89. Kudernatsch M, Sutor B. 1994. Cholinergic modulation of dopamine overflow in the rat neostriatum: a fast cyclic voltammetric study in vitro. Neurosci Lett 181:107-12.
90. Lacey MG, Calabresi P, North RA. 1990. Muscarine depolarizes rat substantia nigra zona compacta and ventral tegmental neurons in vitro through M1-like receptors. J Pharmacol Exp Ther 253:395-400.
91. Lang AE, Lozano AM. 1998. Parkinson's disease. N Engl J Med 339:1130-43.
92. Laudenbach V, Media F, Zoli M, Rossi FM, Evrard P, Changeux JP, and others. 2002. Selective activation of central subtypes of the nicotinic acetylcholine receptor has opposite effects on neonatal excitotoxic brain injuries. FASEB J 16:423-5.
93. Lehmann J, Langer SZ. 1982. Muscarinic receptors on dopamine terminals in the cat caudate nucleus: neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine. Brain Res 248:61-9.
94. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. 1991. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218-26.
95. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, and others. 1998. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 71:2439-46.
96. Magnin M, Morel A, Jeanmonod D. 2000. Single-unit analysis of the pallidum, thalamus, and subthalamic nucleus in parkinsonian patients. Neuroscience 96:549-64.
97. Mansvelder HD, Keath JR, McGehee DS. 2002. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33:905-19.
98. Mansvelder HD, McGehee DS. 2000. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27:349-57.
99. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. 1995. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269:1692-6.
100. Meltzer HY, Chai BL, Thompson PA, Yamamoto BK. 1994. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J Pharmacol Exp Ther 268:1452-61.
101. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
102. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. 1995. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45:1041-51.
103. Nicola SM, Surmeier J, Malenka RC. 2000. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 23:185-215.
104. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L. 1997. Cigarette smoking is associated with abnormal involuntary movements in the general male population - a study of men born in 1933. Biol Psychiatry 41:717-23.
105. Oorschot DE. 1996. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol 366:580-99.
106. Ott BR, Lannon MC. 1992. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 15:322-5.
107. Owens DGC. 1999. A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge (UK): Cambridge University Press.
108. Parent A, Sato F, Wu Y, Gauthier J, Levesque M, Parent M. 2000. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci 23:S20-27.
109. Phelps PE, Houser CR, Vaughn JE. 1985. Immunocytochemical localization of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. J Comp Neurol 238:286-307.
110. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, and others. 1998. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-7.
111. Pidoplichko VI, De Biasi M, Williams JT, Dani JA. 1997. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390:401-4.
112. Pineda JC, Bargas J, Flores-Hernandez J, Galarraga E. 1995. Muscarinic receptors modulate the afterhyperpolarizing potential in neostriatal neurons. Eur J Pharmacol 281:271-7.
113. Pisani A, Bonsi P, Centonze D, Calabresi P, Bernardi G. 2000. Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J Neurosci 20:RC69.
114. Pittaluga A, Versace P, Marchi M, Raiteri M. 1987. Pirenzepine binding in rat corpus striatum decreases after hemitransection of the nigro-striatal pathway. Fund Clin Pharmacol 1:317-25.
115. Pothos EN, Davila V, Sulzer D. 1998. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J Neurosci 18:4106-18.
116. Raz A, Vaadia E, Bergman H. 2000. Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and tremulous 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine vervet model of parkinsonism. J Neurosci 20:8559-71.
117. Riggs JE. 1992. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharmacol 15:88-99.
118. Roberts RC, Force M, Kung L. 2002. Dopaminergic synapses in the matrix of the ventrolateral striatum. Synapse 45:78-85.
119. Role LW, Berg DK. 1996. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16:1077-85.
120. Saka E, Iadarola M, Fitzgerald DJ, Graybiel AM. 2002. Local circuit neurons in the striatum regulate neural and behavioral responses to dopaminergic stimulation. Proc Natl Acad Sci U S A 99:9004-9.
121. Salamone JD, Correa M, Carlson BB, Wisniecki A, Mayorga AJ, Nisenbaum E, and others. 2001. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci 68:2579-84.
122. Schultz W, Dayan P, Montague PR. 1997. A neural substrate of prediction and reward. Science 275:1593-9.
123. Scroggs RS, Cardenas CG, Whittaker JA, Kitai ST. 2001. Muscarine reduces calcium-dependent electrical activity in substantia nigra dopaminergic neurons. J Neurophysiol 86:2966-72.
124. Smolders I, Bogaert L, Ebinger G, Michotte Y. 1997. Muscarinic modulation of striatal dopamine, glutamate, and GABA release, as measured with in vivo microdialysis. J Neurochem 68:1942-8.
125. Spanagel R, Weiss F. 1999. The dopamine hypothesis of reward: past and current status. Trends Neurosci 22:521-7.
126. Sugita S, Uchimura N, Jiang ZG, North RA. 1991. Distinct muscarinic receptors inhibit release of γ-aminobutyric acid and excitatory amino acids in mammalian brain. Proc Natl Acad Sci U S A 88:2608-11.
127. Terman D, Rubin JE, Yew AC, Wilson CJ. 2002. Activity patterns in a model for the subthalamopallidal network of the basal ganglia. J Neurosci 22:2963-76.
128. Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T. 2000. Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J Neurosci 20:7067-73.
129. Uchimura N, North RA. 1990. Muscarine reduces inwardly rectifying potassium conductance in rat nucleus accumbens neurones. J Physiol 422:369-80.
130. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. 2001. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 57:1032-5.
131. Weiler MH. 1989. Muscarinic modulation of endogenous acetylcholine release in rat neostriatal slices. J Pharmacol Exp Ther 250:617-23.
132. Weiner DM, Levey AI, Brann MR. 1990. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci U S A 87:7050-4.
133. Wess J. 1996, Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 10:69-99.
134. West AR, Grace AA. 2002. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 22:294-304.
135. Westerink BH, de Boer P, Damsma G. 1990. Dopamine-acetylcholine interaction in the striatum studied by microdialysis in the awake rat: some methodological aspects. J Neurosci Methods 34:117-24.
136. Whitehead KJ, Rose S, Jenner P. 2001. Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats. Eur J Neurosci 14:851-60.
137. Wilson CJ. 1998. Basal ganglia. In: Shepherd GM, editor. The synaptic organization of the brain. Oxford (UK): Oxford University Press. p 279-316.
138. Wilson CJ, Chang HT, Kitai ST. 1990. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum. J Neurosci 10:508-19.
139. Wonnacott S. 1997. Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92-8.
140. Xu M, Mizobe F, Yamamoto T, Kato T. 1989. Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats. Brain Res 495:232-42.
141. Yan Z, Flores-Hernandez J, Surmeier DJ. 2001. Coordinated expression of muscarinic receptor messenger RNAs in striatal medium spiny neurons. Neuroscience 103:1017-24.
142. 2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J Neurophysiol 77:1003-15.
143. 2+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway. J Neurosci 16:2592-604.
144. Yassa R, Lal S, Korpassy A, Ally J. 1987. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 22:67-72.
145. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. 2002. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 22:1709-17.
146. Zhou FM, Liang Y, Dani JA. 2001. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4:1224-9.